Arix Bioscience PLC (ARIX) Result of Annual General Meeting 2022
07-Jun-2022 / 16:44 GMT/BST Dissemination of a Regulatory
Announcement, transmitted by EQS Group. The issuer is solely
responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Result of Annual General Meeting 2022
LONDON, 7 June 2022: Arix Bioscience plc ("Arix" or the
"Company") (LSE: ARIX), announces that at its Annual General
Meeting (the "Meeting") duly convened and held today, all
resolutions as set out on the notice of meeting were duly passed by
way of a poll. Resolutions 1 to 11 were passed as ordinary
resolutions. Resolutions 12 to 15 were passed as special
resolutions.
Full details of the poll results are set out below and will also
be available on the Company's website.
VOTES TOTAL % of VOTES
No RESOLUTION VOTES FOR % AGAINST % VOTES ISC WITHHELD
VOTED
To receive the Directors' Report and the
1 accounts of the Company for the year ended 63,669,622 99.99% 5,609 0.01% 63,675,231 49.29% 10,853
31 December 2021
2 To approve the Directors' Remuneration 63,589,770 99.90% 65,188 0.10% 63,654,958 49.28% 31,126
Policy
3 To approve the Directors' Remuneration 60,232,861 94.62% 3,422,747 5.38% 63,655,608 49.28% 30,476
Report
4 To re-elect Peregrine Moncreiffe as a 60,068,424 94.35% 3,599,164 5.65% 63,667,588 49.29% 18,496
Director
5 To re-elect Maureen O'Connell as a Director 59,600,160 93.61% 4,068,028 6.39% 63,668,188 49.29% 17,896
6 To re-elect Isaac Kohlberg as a Director 63,450,417 99.66% 217,771 0.34% 63,668,188 49.29% 17,896
7 To re-elect Robert Lyne as a Director 63,451,455 99.66% 216,733 0.34% 63,668,188 49.29% 17,896
8 To elect Sir Michael Bunbury as a Director 60,231,844 94.60% 3,436,344 5.40% 63,668,188 49.29% 17,896
9 To appoint BDO LLP as auditors of the 63,659,891 99.98% 12,947 0.02% 63,672,838 49.29% 13,246
Company
To authorise the Audit and Risk Committee of
10 the Company to fix the auditor's 63,667,766 99.99% 4,772 0.01% 63,672,538 49.29% 13,546
remuneration
11 To authorise the Directors to allot shares 63,632,590 99.94% 40,130 0.06% 63,672,720 49.29% 13,364
12 Authority to disapply statutory pre- emption 58,648,467 92.11% 5,021,253 7.89% 63,669,720 49.29% 16,364
rights
13 Additional authority to disapply statutory 58,653,953 92.12% 5,015,767 7.88% 63,669,720 49.29% 16,364
pre- emption rights
14 To authorise the Company to purchase its own 63,648,630 99.96% 22,560 0.04% 63,671,190 49.29% 14,894
shares
Authority to call a general meeting, other
15 than an annual general meeting, on not less 63,666,745 99.99% 8,786 0.01% 63,675,531 49.29% 10,553
than 14 clear days' notice
In accordance with Listing Rule 9.6.2, copies of resolutions
passed at the Meeting concerning items other than ordinary business
will shortly be available for inspection on the National Storage
Mechanism, which can be accessed at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions considered at the AGM are
contained in the Notice of AGM, published on 12 May 2022, which is
available on Arix investor relations website.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in breakthrough biotechnology companies around
cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise, and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: RAG
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 166768
EQS News ID: 1370371
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1370371&application_name=news
(END) Dow Jones Newswires
June 07, 2022 11:44 ET (15:44 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2024 to Jun 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Jun 2023 to Jun 2024